Skip to main content
Prescription drug costs image by TaxRebate.org.uk via Flickr

The Case for a Public Option for the Drug Industry

Dana Brown

Dana Brown

Director of the Next System Project more

Isaiah J. Poole

Isaiah J. Poole

Editorial Manager, The Next System Project more

Health & Wellbeing

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached a tentative settlement with some of the plaintiffs in which Purdue would transform itself through the bankruptcy process from a typical, profit-chasing drugmaker into a “public beneficiary company.” The proposition raises an important question: If plaintiffs are open to the idea of turning Purdue into a public trust run by appointees of a federal bankruptcy judge—one that would distribute its profits to state and local governments—why not take one more step? Why not create the beginnings of a network of public pharmaceutical companies like those that already exist in such countries as Sweden, Brazil, and Thailand?

Continue reading in The New Republic »

Dana Brown

Dana Brown

Director of the Next System Project more

Isaiah J. Poole

Isaiah J. Poole

Editorial Manager, The Next System Project more

More related work

System Change magazine highlights a year of bold ideas

The Democracy Collaborative and the Next System Project has published System Change, a magazine that captures the bold ideas and groundbreaking work of our leaders and scholars in 2019. read more
A blister pack of medicine in pill form

Commitments to public pharmaceutical production in the Democratic primary

Our report Medicine For All: The Case for a Public Option in the Pharmaceutical Industry  argues that truly making pharmaceuticals accessible and affordable for all Americans will require public ownership of pharmaceutical production read more
A pipette being dipped into an array of testtubes

A National Pharmaceutical Research and Development Institute

To promote the execution of pharmaceutical R&D in the public interest, the US should establish a national pharmaceutical R&D institute for full-cycle drug development, which will help promote long-term access to medicines, reignite innovation, and ensure prioritization of public health needs. read more